Core Insights - Shenzhen Jindu Biomedical Technology Co., Ltd. has completed a Pre-A+ round financing, raising tens of millions of RMB, with participation from Nanshan Zhanxin Investment [1][2]. Financing Details - The financing round occurred on November 13, 2025, with Nanshan Zhanxin Investment as the investor [2]. - Previous financing rounds include: - Pre-A round on November 4, 2025, with undisclosed investment from Chuang Dongfang Investment [2]. - Angel+ round on October 14, 2025, raising tens of millions of RMB from HongShan Sequoia China [2]. - Angel round on November 30, 2023, with tens of millions of RMB from Xiantong Capital [2]. - Seed round on February 28, 2023, raising millions of RMB from Shenzhen Jibei Investment Partnership [2]. Company Focus - Jindu Biomedical is focused on developing multimodal medical diagnostic models, emphasizing multi-omics analysis (RNA, DNA, protein, and metabolomics) to enhance diagnostic capabilities [2]. - The first expert model, GeneLLM, is pre-trained on 23 billion sequencing sequences and 3.45 trillion base data, transforming complex biological data into precise medical decision support tools [2]. - The technology leverages research collaboration from top universities, including Oxford University, Peking University, Tsinghua University, and Beihang University, aiming to revolutionize medical diagnostics by integrating multiple omics data for comprehensive disease diagnosis [2].

Core Viewpoint - The article emphasizes the integration of AI tools, particularly DeepSeek, in enhancing research methodologies in bioinformatics, specifically in the analysis of multi-omics data and the design of research projects [1][3][29]. Course Structure - The course includes practical sessions on AI-assisted design of research topics, focusing on multi-omics data analysis, including metabolomics, proteomics, and genomics [3][30]. - It covers the use of AI for efficient reading and summarizing of CNS literature, as well as the evaluation of innovative ideas and data analysis feasibility in bioinformatics [3][29]. AI Applications in Bioinformatics - AI is utilized for sample grouping, data filtering from public databases, and visualizing bioinformatics analysis results [4][19]. - The course includes modules on machine learning applications in metabolomics, proteomics, and transcriptomics, highlighting various algorithms and their implementations [33][40]. Research Methodologies - The curriculum emphasizes the importance of understanding and applying various statistical and machine learning methods for data analysis, including regression models and clustering techniques [44][40]. - It also includes practical coding sessions to replicate high-level research from CNS articles, enhancing hands-on experience [50][51]. Continuous Support and Learning - The program offers ongoing support and one-on-one guidance even after course completion, ensuring that participants can effectively apply their learning in real-world scenarios [22][24][50]. - The course is designed to be flexible, allowing participants to revisit materials and receive assistance as needed [22][26].

Group 1 - The company reported a significant increase in performance for H1 2025, with revenue reaching 307 million yuan, a year-on-year growth of 17.6%, and net profit attributable to shareholders increasing by 59.0% and 88.5% for the non-deduction and deduction cases respectively [1] - In Q2 2025, revenue was 151 million yuan, showing a year-on-year increase of 4.8%, while net profit attributable to shareholders was 63 million yuan and 59 million yuan, reflecting year-on-year growth of 44.5% and 71.4% respectively [1] - The company maintains its profit forecasts for 2025-2027, predicting net profits of 192 million, 230 million, and 276 million yuan, with corresponding EPS of 1.14, 1.37, and 1.64 yuan, indicating a PE ratio of 24.8, 20.7, and 17.2 times [1] Group 2 - The domestic market continues to benefit from the new national standards, driving growth in ARA and DHA, with expectations for continued revenue growth in H2 2025 [2] - The gross profit margin has significantly improved, with a year-on-year increase of 7.24 percentage points and a quarter-on-quarter increase of 1.87 percentage points, attributed to scale effects and reduced costs [2] - The net profit margin for Q2 2025 reached 41.76%, with a year-on-year increase of 11.46 percentage points, indicating strong profitability [2] Group 3 - The restructuring target, Ouyi Biological, has committed to a cumulative net profit of no less than 270 million yuan from 2025 to 2027, averaging 90 million yuan per year, indicating high growth potential [3] - Ouyi Biological is in the early stages of multi-omics analysis, with significant opportunities for overseas market expansion and technological application [3] - The completion of the asset restructuring is expected to enhance the company's foundational R&D capabilities and accelerate new product development [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a record high quarterly profit, maintaining an optimistic outlook for the second half of 2025 [4] - The company's revenue for H1 2025 reached 307 million yuan, a year-on-year increase of 17.6%, with net profit attributable to the parent company growing by 59.0% and 88.5% for the non-deduction and deduction cases respectively [4][5] - The acquisition of Ouyisheng Biological is anticipated to enhance the company's development potential, with a projected cumulative net profit of no less than 270 million yuan from 2025 to 2027 [7] Financial Performance - In Q2 2025, the company's revenue was 151 million yuan, a year-on-year increase of 4.8%, with net profit attributable to the parent company increasing by 44.5% and 71.4% for the non-deduction and deduction cases respectively [4][5] - The gross profit margin in Q2 2025 improved significantly, with a year-on-year increase of 7.24 percentage points, reaching 41.76% [6] - The company forecasts net profits of 192 million, 230 million, and 276 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS predictions of 1.14, 1.37, and 1.64 yuan [4][9] Market Outlook - The domestic market is benefiting from new national standards, driving growth in ARA and DHA products [5] - The company expects continued revenue growth in the domestic market for Q2 2025, while international market revenue may slightly decline due to high base effects [5] - The second half of 2025 is expected to bring additional growth opportunities in the health food sector, particularly for DHA products [5] Valuation Metrics - The current stock price corresponds to P/E ratios of 24.8, 20.7, and 17.2 for the years 2025, 2026, and 2027 respectively [4][9] - The company’s total market capitalization is 4.753 billion yuan, with a circulating market capitalization also at 4.753 billion yuan [1]